Teva Pharmaceutical Industries (TEVA) Free Cash Flow (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Free Cash Flow for 18 consecutive years, with $307.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Free Cash Flow rose 134.35% year-over-year to $307.0 million; the trailing twelve-month figure through Jun 2026 stood at $1.3 billion (up 51.46% YoY), and the FY2025 full-year result was $1.1 billion, up 53.27% from the prior year.
• Free Cash Flow climbed to $307.0 million in Q2 2026 per TEVA's latest filing, from -$208.0 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $1.1 billion in Q4 2023 and bottomed at -$284.0 million in Q1 2023.
• Historically, Free Cash Flow has averaged $215.6 million across 5 years, with a median of $168.0 million in 2023.
• The widest YoY moves for Free Cash Flow: up 5225.0% in 2023, down 134.2% in 2023.
• Over 5 years, Free Cash Flow stood at $831.0 million in 2022, then advanced by 28.16% to $1.1 billion in 2023, then slumped by 58.12% to $446.0 million in 2024, then surged by 127.8% to $1.0 billion in 2025, then tumbled by 69.78% to $307.0 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered $307.0 million, -$208.0 million, and $1.0 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.